- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06217185
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Early Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050000
- Recruiting
- The Fourth Hospital of Hebei Medical University
-
Contact:
- Lina zhang
- Phone Number: 18531117825
- Email: linazh_001@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 18-70 years old, female;
Pathological examination confirmed HER-2 positive invasive breast cancer; (HER2 positivity is defined as an immunohistochemical (IHC) score of 3+ or in-situ hybridization (ISH) result for HER2 gene amplification in >10% of immunoreactive cells.
HER2 positivity needs to be verified by the pathology department of the research center involved in this study)
- Imaging confirmed recurrent/metastatic breast cancer;
- Patients who relapsed and metastasized three months after discontinuation of Trastuzumab treatment;
- Have at least one measurable lesion (according to RECIST 1.1 criteria);
- ECOG score of 0-2;
- Expected life span ≥3 months;
- Normal major organ function;
- The researcher believes that the participant may benefit;
- Volunteer to participate in this study, sign informed consent.
Exclusion Criteria:
Patients who meet any of the following criteria are not eligible for participation:
- Have any confirmed history of drug allergies, or severe allergic reactions to any component of the investigational drug (NCI-CTCAE 5.0 grade > 3);
- Patients in advanced stages who have undergone systemic treatment;
- A history of serious heart diseases such as congestive heart failure, unstable angina, arrhythmia or myocardial infarction;
- Suffer from serious pulmonary diseases, such as interstitial lung disease or pneumonia, pulmonary fibrosis, acute pulmonary diseases, etc.;
- Currently suffering from severe liver-related diseases, such as acute hepatitis, explosive hepatitis, coagulation factor synthesis disorder, etc.; Those who are positive for HBV surface antigen or HBV core antibody must have a peripheral blood Hepatitis B virus DNA titer test < 1×10 ^3 IU/ml in order to participate;
- Comorbidity or condition that may interfere with their participation in the study, or any serious medical impediment that might affect participant's safety (such as, active or uncontrolled infection, active liver/gallbladder disease requiring antiviral treatment);
- Other invasive tumors (including second primary breast cancer) that may affect the evaluation of results and adherence to the protocol;
- Having undergone major surgical procedure or are yet to recover from major internal diseases within the 4 weeks prior to the study;
- Any circumstance that the researcher considers the participant unfit to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental arm
Pyrotinib, Trastuzumab Combined With Taxanes *When taxane drugs are discontinued (after completing 6-8 cycles of treatment or due to intolerance), the therapy can be continued with the combination of metronomic capecitabine and trastuzumab, along with pyrotinib. |
Pyrotinib 400mg qd po continuously
For Trastuzumab, the loading dose for the first treatment cycle is 8 mg/kg, and for subsequent cycles, 6 mg/kg.
It is to be used once every three weeks
Taxanes: Usual clinical dose is administered, in a 21-day cycle.
Capecitabine: 650mg/m2 each time, given twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: 24months
|
the period of time from the start of treatment for cancer patients to the observation of disease progression, or death due to any reason
|
24months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CNS-PFS
Time Frame: 24months
|
the period of time from the start of treatment for cancer patients to the observation of intracranial progression , or death due to any reason
|
24months
|
ORR
Time Frame: 24months
|
the proportion of patients who have a partial or complete response to therapy
|
24months
|
DCR
Time Frame: 24months
|
the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention in clinical trials of anticancer agents
|
24months
|
OS
Time Frame: 24months
|
the period of time from the start of treatment for cancer patients to the observation of death due to any reason
|
24months
|
Overall Number of Participants Who Experienced at Least One Adverse Event, Including Serious and Non-Serious Adverse Events
Time Frame: 24months
|
Adverse event (AE) severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI-CTCAE v5.0); if the AE was not specifically listed, the following grades of severity were used: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening or disabling; and Grade 5 = death.
Severe and serious are not synonymous.
Severity refers to the intensity of an AE, whereas a serious AE must meet criteria set out in the protocol; both were independently assessed for each AE.
Only the most severe intensity was counted for multiple occurrences of the same AE in one participant.
|
24months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OBU-BC-II-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Breast Cancer
-
Abramson Cancer Center at Penn MedicineActive, not recruitingAdvanced Breast Cancer | Metastatic Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Locally Advanced Breast CancerUnited States
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
Puma Biotechnology, Inc.CompletedBreast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid TumorsUnited States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
-
Zhejiang Cancer HospitalJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingFemale Breast Cancer Patients | Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | HRD Positive Advanced Breast Cancer
-
Introgen TherapeuticsCompletedLocally Advanced Breast Cancer (LABC)United States
-
University of UtahCelgene CorporationCompletedAdvanced or Metastatic Solid Tumors | Advanced or Metastatic Breast CancerUnited States
-
University Hospital TuebingenRecruitingAdvanced/Metastatic Breast Cancer | Breast Cancer (Early Breast Cancer)Germany
-
National Center of Oncology, ArmeniaBRIU GmbHCompletedAdvanced Breast Cancer | Metastatic Breast CancerArmenia
-
SanofiCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast CancerUnited States
-
AstraZenecaCompletedAdvanced Breast Cancer | Metastatic Breast CancerJapan
Clinical Trials on Pyrotinib
-
Hunan Cancer HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingHER2-positive Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.Cancer Institute and Hospital, Chinese Academy of Medical SciencesCompleted
-
Peking Union Medical CollegeUnknownBreast Cancer | HER2 Gene MutationChina
-
Tongji UniversityUnknownNon-small Cell Lung CancerChina
-
Tianjin Medical University Cancer Institute and...UnknownNon Small Cell Lung CancerChina
-
Henan Cancer HospitalJiangsu HengRui Medicine Co., Ltd.Active, not recruitingMetastatic Breast CancerChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownNon Small Cell LungChina
-
RemeGen Co., Ltd.Not yet recruitingNon-small Cell Lung CancerChina
-
Second Affiliated Hospital, School of Medicine,...Zhejiang Cancer Hospital; First Affiliated Hospital of Zhejiang University; Sir... and other collaboratorsUnknownColorectal CancerChina
-
The First Affiliated Hospital with Nanjing Medical...First Affiliated Hospital of Wenzhou Medical UniversityRecruiting